EIF2AK2 and Alzheimer disease: Considering recent reports on failures in AD clinical trials by targeting amyloid β [45, 46] (but also see [47]), pharmacological interventions enhancing plasticity such as suppressing PKR may provide a promising alternative strategy for developing AD treatment.